Demonstration Formulary
1 Gastro-intestinal system
fgsdfgsdfgs
01-03-01 H2-receptor antagonists
| Ranitidine |
|
Formulary
|
For use in patients with swallowing difficulties or via nasogastric tubes only |
 NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
|
| Ranitidine |
|
Formulary
|
The European Medicines Agency (EMA) Human Medicines Committee (CHMP) has recommended the suspension of all ranitidine medicines due to the presence of low levels of the impurity N-nitrosodimethylamine (NDMA). (30 April 2020)
|
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
|
| Ranitidine |
|
Formulary
|
|
West Midlands Palliative Care Physicians Guidelines |
|
|
Links
- NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- PHE: Helicbacter pylori in dyspepsia: test and treat (diagnosis and treatment guide for primary care)
- West Midlands Palliative Care Physicians Guidelines